Sophia Genetics (SOPH) news
Recent news
Binance will extend the Monitoring Tag to include GLMR, ICX, MOVR, RARE, and SOPH.
AInvest Wire · Aug 11, 2026Sophia Genetics SA Q2 adjusted gross margin 72.1%
AInvest Wire · Aug 4, 2026Sophia Genetics SA Q2 revenue USD 23.3 million
SOPHiA GENETICS (Nasdaq: SOPH) reported second-quarter revenue of $23.3 million for the period ending June 30, 2026, reflecting continued growth in its core genomics business and expanding adoption of SOPHiA DDM™ . This represents a significant increase compared to the $18.3 million in revenue…
AInvest Wire · Aug 4, 2026Sophia Genetics: enters multi-year collaboration with AstraZeneca on two companion diagnostics
SOPHiA GENETICS (Nasdaq: SOPH) has entered into a multi-year collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and deploy two companion diagnostic (CDx) solutions aimed at improving the diagnosis and treatment of breast and prostate cancers. The partnership builds on the companies’…
AInvest Wire · Aug 4, 2026Sophia Genetics SA: H.C. Wainwright initiates coverage with buy rating; price target $12
H.C. Wainwright & Co. has initiated coverage of Sophia Genetics SA (SOHG), assigning the company a "Buy" rating and setting a price target of $12 per share. The firm highlighted Sophia Genetics' position in the growing genomic data analytics market and its potential for long-term growth. The…
AInvest Wire · Jul 20, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.